• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

    10/20/25 4:23:01 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Astria Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    04635X102

    (CUSIP Number)


    10/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04635X102


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    163,238.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    163,238.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    163,238.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    04635X102


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    222,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    222,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    222,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    04635X102


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    222,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    222,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    222,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    04635X102


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    222,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    222,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    222,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Astria Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    22 Boston Wharf Road, 10th Floor, Boston, Massachusetts 02210
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    04635X102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/17/2025
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/17/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/17/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:10/17/2025

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of October 17, 2025, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $ATXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXS

    DatePrice TargetRatingAnalyst
    9/17/2025$16.00 → $20.00Buy
    H.C. Wainwright
    4/29/2025$47.00Overweight
    Cantor Fitzgerald
    1/31/2025$26.00Mkt Outperform
    JMP Securities
    7/29/2024$35.00Buy
    TD Cowen
    3/28/2023$18.00Outperform
    Evercore ISI
    9/29/2021$20.00Buy
    Jefferies
    More analyst ratings

    $ATXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Agarwal Sunil

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:16:46 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bate Kenneth

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:15:46 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cole Hugh M

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:14:39 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Astria Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously

    9/17/25 11:36:24 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

    4/29/25 8:10:45 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Astria Therapeutics with a new price target

    JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00

    1/31/25 6:57:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that the companies have entered into a definitive agreement under which BioC

    10/14/25 7:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the Canadian Society of Allergy and Clinical Immunology (CSACI) 80th Anniversary Scientific Meeting, taking place October 15-18, 2025 in Vancouver, British Columbia. Dr. Adil Adatia, M.D., FRCPC, University of Alberta, Edmonton, AB will share initial results from the ALPHA-SOLAR long-term trial of navenibart in a presentation of a poster titled, "Long-term safety, efficacy, and quality of life (QoL) of navenibart in hereditary angioedema (HAE): Initial results from ALPHA-SOLAR." Kusum

    10/9/25 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Astria Therapeutics Inc.

    SCHEDULE 13D - Astria Therapeutics, Inc. (0001454789) (Subject)

    10/24/25 11:00:54 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

    SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    10/20/25 4:23:01 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.

    SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    10/16/25 8:52:53 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $29,999,522 worth of shares (2,481,350 units at $12.09) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    2/5/24 5:02:33 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $4,588,000 worth of shares (740,000 units at $6.20) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    12/22/23 2:51:57 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $6,999,997 worth of shares (1,074,608 units at $6.51) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    10/18/23 4:11:36 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Leadership Updates

    Live Leadership Updates

    View All

    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

    4/9/24 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Financials

    Live finance-specific insights

    View All

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that the companies have entered into a definitive agreement under which BioC

    10/14/25 7:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

    -- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

    3/25/24 7:30:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:46:12 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:45:56 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Astria Therapeutics Inc.

    SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 4:41:28 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care